Ionis CEO: $3B Tryngolza Opportunity and the Next Wave of RNA Drugs

Why It Matters

The FDA decision on Tryngolza could create a $3 billion market for a first‑in‑class triglyceride therapy, while Pelacarsen’s outcomes data may open a new, lucrative avenue for treating Lp(a)‑driven cardiovascular disease.

Key Takeaways

• Tryngolza (Olezarsen) shows 85% pancreatitis risk reduction in patients.
• FDA set June 30 PDUFA date for severe hypertriglyceridemia indication.
• Ionis raised US peak sales forecast to $3 billion despite competition.
• Pelacarsen outcomes trial could validate Lp(a) as treatable risk factor.
• Ionis expanding into siRNA, developing next‑gen dosing for RNA drugs.

Summary

Ionis Pharmaceuticals CEO Brett Monia discussed the company’s near‑term catalysts, focusing on the upcoming FDA decision for Olezarsen, branded Tryngolza, in severe hypertriglyceridemia (SHTG). The drug, already approved for the rare genetic disease familial chylomicronemia syndrome, demonstrated an 85% reduction in acute pancreatitis events in a Phase 3 trial, prompting breakthrough therapy designation and a PDUFA date of June 30. Monia highlighted that Tryngolza lowered triglycerides by more than 70% and pushed the majority of patients below the 500 mg/dL threshold, establishing a high efficacy bar. He announced an upgraded U.S. peak‑sales outlook of over $3 billion, explicitly factoring in competition from Arrowhead’s siRNA candidate Plozasiran, and emphasized the durability of first‑mover advantage and the market’s capacity for multiple players. The discussion also turned to Pelacarsen, Ionis’s Lp(a)‑lowering asset partnered with Novartis. The HORIZON outcomes trial, enrolling 8,300 patients, will be read out later this year and could confirm Lp(a) as a modifiable cardiovascular risk factor. Monia noted that a positive readout would unlock a multi‑billion‑dollar royalty stream and reinforce Ionis’s reputation as a pioneer in RNA therapeutics. Finally, Monia outlined Ionis’s strategic shift toward siRNA platforms, citing a follow‑on siRNA candidate for SHTG that aims for semi‑annual dosing. By diversifying its technology stack and building next‑generation molecules, Ionis seeks to protect its market leadership and extend franchise value for decades.

Original Description

Ionis CEO Dr. Brett Monia explains why the company may be entering one of the most important stretches in its history, with Tryngolza facing a June 30 FDA decision in severe hypertriglyceridemia and Pelacarsen's HORIZON outcomes data expected soon. He also discusses Ionis' shift from discovery partner to fully integrated biotech, its growing antisense and siRNA platform, CNS ambitions, and the path toward cash-flow breakeven in 2028.

Topics covered:

• Tryngolza/Olezarsen and the severe hypertriglyceridemia opportunity

• The 85% pancreatitis event reduction shown in Phase 3 data

• Why Ionis raised U.S. peak sales guidance to $3 billion-plus

• Pelacarsen, Lp(a), and the HORIZON cardiovascular outcomes trial

• Competition from siRNA drugs and Ionis' next-generation follow-on molecules

• CNS programs, blood-brain-barrier delivery, and the Bicycle Therapeutics partnership

• Ionis' transition from licensing-focused R&D shop to integrated biotech

• Cash-flow breakeven goals, pipeline readouts, and what investors may be missing

Dr. Brett Monia, CEO of Ionis Pharmaceuticals, joins Karl Thiel for this interview.

---

This video is brought to you by The Motley Fool. Visit https://fool.com/Invest to get access to this special offer. The Motley Fool Stock Advisor returns are 936% as of 6/16/2026 and measured against the S&P 500 returns of 208% as of 6/16/2026. Past performance is not an indicator of future results. All investing involves a risk of loss. Individual investment results may vary, not all Motley Fool Stock Advisor picks have performed as well.